Impact of Drug Cost Containment, Drug Price Revisions and Promotion of Generic Drugs
First written in FY2016. 26 of 36 entries say "Materialised", first in FY2016. Latest entry: FY2026.
Mochida Pharmaceutical moved to the "Worse" side of this theme in 2019, 1 year before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
17 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「Although the pharmaceuticals-related business was affected by drug price revisions and the selected medical care system for long-listed products introduced in October 2024, sales grew mainly due to the growth of new drugs, reaching ¥109,042 million, an increase of 11.3% from the previous fiscal year. Sales of long-listed products and generic drugs fell below the previous fiscal year's level.」
While the effects of drug price revisions and the selected medical care system emerged as declines in sales of long-listed products and generic drugs, total sales in the pharmaceuticals-related business increased due to the growth of new drugs. - FY2026-H1MaterialisedAnnual report
「Although the pharmaceuticals-related business was affected by drug price revisions and the selected medical care system for long-listed products introduced in October 2024, sales grew mainly due to the growth of new drugs, reaching ¥51,058 million, a year-on-year increase of 7.4%. Sales of long-listed products fell below the same period of the previous year.」
The disclosure states that the effects of drug price revisions and the selected medical care system for long-listed products emerged, causing sales of long-listed products to fall below the same period of the previous year. Meanwhile, total sales in the pharmaceuticals-related business increased due to the growth of new drugs. - FY2025MaterialisedAnnual report
「Although the pharmaceuticals-related business was affected by drug price revisions and the selected medical care system for long-listed products introduced in October 2024, sales grew mainly due to the growth of new drugs, reaching ¥97,989 million, an increase of 1.6% from the previous fiscal year. Sales of long-listed products and generic drugs fell below the previous fiscal year's level.」
The disclosure states that the effects of drug price revisions and the selected medical care system for long-listed products emerged, and that sales of long-listed products and generic drugs fell below the previous fiscal year's level. - FY2025-H1MaterialisedAnnual report
「In terms of profit, operating profit was ¥3,793 million, a year-on-year decline of 4.0%, due to an increase in the cost-of-sales ratio resulting from drug price revisions and higher import prices for active pharmaceutical ingredients and drug products caused by the weaker yen, among other factors.」
The effects of drug price revisions appeared in results as an increase in the cost-of-sales ratio and a 4.0% year-on-year decline in operating profit. - FY2024MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions and the entry of a generic version of the antidepressant Lexapro into the market in December 2022, and sales were ¥96,455 million, a 0.9% decline from the previous fiscal year.」
The effects of drug price revisions and the entry of a generic version of Lexapro appeared in FY2024 results as a 0.9% decline in sales in the pharmaceuticals-related business from the previous fiscal year. - FY2024-Q3MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions and the launch of a generic version of the antidepressant Lexapro in December 2022, and sales were ¥73,184 million, a 4.7% year-on-year decline.」
The effects of drug price revisions and the launch of a generic version of Lexapro appeared in results for the first 3 quarters of the fiscal year as a 4.7% year-on-year decline in sales in the pharmaceuticals-related business. - FY2024-Q2MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions and the launch of a generic version of the antidepressant Lexapro in December 2022, and sales were ¥46,286 million, a 7.8% year-on-year decline.」
The effects of drug price revisions and the launch of a generic version of Lexapro appeared in results as a 7.8% year-on-year decline in sales in the pharmaceuticals-related business. - FY2024-Q1MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions and the launch of a generic version of the antidepressant Lexapro in December 2022, and sales were ¥23,140 million, an 11.8% year-on-year decline.」
The effects of drug price revisions and the launch of a generic drug appeared in first-quarter results as an 11.8% year-on-year decline in sales in the pharmaceuticals-related business. - FY2023MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions, and sales were ¥97,340 million, a 6.8% decline from the previous fiscal year.」
The effects of drug price revisions appeared in full-year results as a 6.8% decline in sales in the pharmaceuticals-related business from the previous fiscal year. - FY2023-Q3MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions, and sales were ¥76,767 million, a year-on-year decline of 4.6%.」
The effects of drug price revisions appeared as a 4.6% year-on-year decline in sales in the pharmaceuticals-related business. - FY2023-Q2MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions, and sales were ¥50,200 million, a year-on-year decline of 1.9%.」
The effects of drug price revisions appeared as a decline in sales in the pharmaceuticals-related business. The disclosure also states that sales of long-listed products fell below the same period of the previous year. - FY2023-Q1MaterialisedAnnual report
「Although the pharmaceuticals-related business was affected by drug price revisions, sales were ¥26,240 million, an increase of 1.0% year on year.……Meanwhile, sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the same period of the previous year.」
The disclosure states that sales of Epadel and Atelec fell below the same period of the previous year amid the continuing effects of drug price revisions. - FY2022MaterialisedAnnual report
「Meanwhile, sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the previous fiscal year's level.」
The effects of drug price revisions, drug cost containment policies and measures to promote generic drug use continued to appear as full-year sales declines for major long-listed products. - FY2022-Q3MaterialisedAnnual report
「Meanwhile, sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the same period of the previous year.」
The effects of drug cost containment policies, the interim-year drug price revision and measures to promote generic drug use, among other factors, continued to appear in results as year-on-year sales declines for Epadel and Atelec. - FY2022-Q2MaterialisedAnnual report
「Meanwhile, sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the same period of the previous year.」
The effects of drug cost containment policies, the interim-year drug price revision and measures to promote generic drug use, among other factors, continued to appear in results as year-on-year sales declines for Epadel and Atelec. - FY2022-Q1MaterialisedAnnual report
「In the pharmaceutical industry, drug cost containment policies driven by the issue of securing funding for social security expenditure continue to advance, and an interim-year drug price revision was carried out in April 2021. Competition among companies has also intensified, and the business environment remains challenging. Meanwhile, sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans; Tramacet, a treatment for chronic pain and post-extraction pain; and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the same period of the previous year.」
The disclosure states that the April 2021 interim-year drug price revision was implemented and that sales of 3 long-listed products fell below the same period of the previous year. The effects of risks arising from drug cost containment policies and the drug pricing system also appeared in the first quarter's results. - FY2021WorsenedAnnual report
「Following drug price revisions in October 2019 and April 2020, the first interim-year revision, distinct from the regular drug price revisions, was carried out in April 2021. Accordingly, the 3-year period beginning in fiscal 2021 is expected to bring an increasingly challenging business environment.」
The disclosure refers to the first interim-year revision in addition to the regular drug price revisions, indicating that the business environment under drug cost containment policies and the drug pricing system is becoming even more challenging. It also reports declining sales of long-listed products. - FY2021-Q3MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans; Tramacet, a treatment for chronic pain and post-extraction pain; and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the same period of the previous year due to the effects of drug price revisions and measures to promote generic drug use, among other factors.」
The effects of drug price revisions and measures to promote generic drug use continued to appear in the third quarter as year-on-year sales declines for Epadel, Tramacet and Atelec. - FY2021-Q2MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans; Tramacet, a treatment for chronic pain and post-extraction pain; and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the same period of the previous year due to the effects of drug price revisions and measures to promote generic drug use, among other factors.」
The effects of drug price revisions and measures to promote generic drug use continued to appear in the second quarter as year-on-year sales declines for Epadel, Tramacet and Atelec. - FY2021-Q1MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans; Tramacet, a treatment for chronic pain and post-extraction pain; and Atelec, a long-acting calcium-channel-blocker antihypertensive, fell below the same period of the previous year due to the effects of drug price revisions and measures to promote generic drug use, among other factors.」
The effects of drug price revisions and measures to promote generic drug use continued to appear in the first quarter as year-on-year sales declines for Epadel, Tramacet and Atelec. - FY2020MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans; Atelec, a long-acting calcium-channel-blocker antihypertensive; and Dinagest, a treatment for endometriosis and adenomyosis, among others, fell below the previous fiscal year's levels due to the effects of measures to promote generic drug use and drug price revisions. Sales of Tramacet, a treatment for chronic pain and post-extraction pain, also fell below the previous fiscal year's level due to the launch of a generic drug in December 2018.」
The effects of drug price revisions, measures to promote generic drug use and the launch of generic drugs have appeared as full-year sales declines for multiple long-listed products and Tramacet. - FY2020-Q3MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and Dinagest, a treatment for endometriosis and adenomyosis, fell below the year-earlier level due to the impact of measures promoting the use of generic drugs and other factors. Sales of Tramacet, a treatment for chronic and post-extraction pain, also fell below the year-earlier level due to the impact of a generic version being launched in December 2018.」
The effects of measures to promote generic drug use and the launch of generic drugs continued to appear in the third quarter as year-on-year sales declines for multiple long-listed products and Tramacet. - FY2020-Q2MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and Dinagest, a treatment for endometriosis and adenomyosis, fell below the year-earlier level due to the impact of measures promoting the use of generic drugs and other factors. Sales of Tramacet, a treatment for chronic and post-extraction pain, also fell below the year-earlier level due to the impact of a generic version being launched in December 2018.」
The effects of measures to promote generic drug use and the launch of generic drugs continued to appear in the second quarter as year-on-year sales declines for multiple long-listed products and Tramacet. - FY2020-Q1MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and Dinagest, a treatment for endometriosis and adenomyosis, fell below the year-earlier level due to the impact of measures promoting the use of generic drugs and other factors. Sales of Tramacet, a treatment for chronic and post-extraction pain, also fell below the year-earlier level due to the impact of a generic version being launched in December 2018.」
The effects of measures to promote generic drug use and the launch of generic drugs continued to appear in the current quarter as year-on-year sales declines for multiple long-listed products and Tramacet. - FY2019MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and Dinagest, a treatment for endometriosis and adenomyosis, fell below the previous fiscal year's level due to the impact of drug price revisions, measures promoting the use of generic drugs, and other factors.」
The impact of drug price revisions and measures promoting the use of generic drugs has emerged as lower full-year sales of multiple long-listed products. - FY2019-Q3RestatedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and Dinagest, a treatment for endometriosis and adenomyosis, fell below the year-earlier level due to the impact of drug price revisions, measures promoting the use of generic drugs, and other factors.」
It reconfirms that sales of multiple long-listed products fell below the year-earlier level due to the impact of drug price revisions and measures promoting the use of generic drugs. - FY2019-Q2RestatedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and Dinagest, a treatment for endometriosis and adenomyosis, fell below the year-earlier level due to the impact of drug price revisions, measures promoting the use of generic drugs, and other factors.」
It reconfirms that sales of multiple long-listed products fell below the year-earlier level due to drug price revisions and measures promoting the use of generic drugs. It also states that there have been no material changes in business and other risks. - FY2019-Q1RestatedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and Dinagest, a treatment for endometriosis and adenomyosis, fell below the year-earlier level due to the impact of drug price revisions, measures promoting the use of generic drugs, and other factors.」
It reconfirms that sales of multiple long-listed products fell below the year-earlier level due to drug price revisions and measures promoting the use of generic drugs. It states that there have been no material changes in business and other risks. - FY2018RestatedAnnual report
「Depending on developments in healthcare cost-containment measures, including future healthcare system reforms, promotion of generic drug use, and reductions in official drug prices, these factors may have a material impact on operating results and financial position.」
It continues to describe the risk of impacts from healthcare system reform, promotion of generic drug use, and reductions in drug prices. - FY2018-Q3RestatedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, and Atelec, a sustained-release calcium-channel blocker antihypertensive, fell below the year-earlier level due to the impact of measures promoting the use of generic drugs and other factors. Sales of Dinagest, a treatment for endometriosis and adenomyosis, also fell below the year-earlier level due to the impact of a generic version being launched in June 2017.」
It continues to state that sales of multiple long-listed products fell below the year-earlier level due to measures promoting the use of generic drugs and the impact of generic drug launches. The impact of the risk has emerged in actual results. - FY2018-Q2MaterialisedAnnual report
「Sales of the long-listed products Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, and Atelec, a sustained-release calcium-channel blocker antihypertensive, fell below the year-earlier level due to the impact of measures promoting the use of generic drugs and other factors. Sales of Dinagest, a treatment for endometriosis, also fell below the year-earlier level due to the impact of a generic version being launched in June 2017.」
It is stated that sales of multiple long-listed products fell below the year-earlier level due to measures promoting the use of generic drugs and the impact of generic drug launches. - FY2018-Q1RestatedAnnual report
「Meanwhile, sales of long-listed products including Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Dinagest, a treatment for endometriosis, and Atelec, a sustained-release calcium-channel blocker antihypertensive, fell below the year-earlier level due to the impact of measures promoting the use of generic drugs and other factors.」
It reconfirms that sales of some long-listed products fell below the year-earlier level due to measures promoting the use of generic drugs. - FY2017-Q3RestatedAnnual report
「Although sales of Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and other products fell below the year-earlier level due to measures promoting the use of generic drugs, drug price revisions, and other factors, sales of Lexapro, an antidepressant, Dinagest, a treatment for endometriosis, Tramacet, a treatment for chronic and post-extraction pain, and generic drugs including biosimilars exceeded the year-earlier level. Revenue was ¥69,561 million, up 0.9% year on year.」
It reconfirms that sales of some core products fell below the year-earlier level due to measures promoting the use of generic drugs and the impact of drug price revisions. - FY2017-Q2RestatedAnnual report
「Although sales of Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and other products fell below the year-earlier level due to measures promoting the use of generic drugs, drug price revisions, and other factors, sales of Lexapro, an antidepressant, Dinagest, a treatment for endometriosis, Tramacet, a treatment for chronic and post-extraction pain, and generic drugs including biosimilars exceeded the year-earlier level. Revenue was ¥44,192 million, up 2.1% year on year.」
It reconfirms that sales of some core products fell below the year-earlier level due to measures promoting the use of generic drugs and drug price revisions. - FY2017-Q1RestatedAnnual report
「Although sales of Epadel, a treatment for hyperlipidemia and arteriosclerosis obliterans, Atelec, a sustained-release calcium-channel blocker antihypertensive, and other products fell below the year-earlier level due to measures promoting the use of generic drugs, drug price revisions, and other factors, sales of Lexapro, an antidepressant, Dinagest, a treatment for endometriosis, Tramacet, a treatment for chronic and post-extraction pain, and generic drugs including biosimilars exceeded the year-earlier level. Revenue was ¥23,442 million, up 8.2% year on year.」
It reconfirms that sales of some core products fell below the year-earlier level due to measures promoting the use of generic drugs and the impact of drug price revisions. - FY2016MaterialisedAnnual report
「The target for the generic drug penetration rate has newly been set at 80% or higher, and the impact on revenue is expected to increase further.」
It is stated that sales of some core products fell below the previous fiscal year due to measures promoting the use of generic drugs and other factors, indicating that the risk has also emerged in actual results.